Somite
Somite (now operating as Cellular Intelligence) is an AI-native TechBio company backed by Khosla Ventures building a universal virtual cell-signaling foundation model to engineer cellular fate. In 2026 the company rebranded from Somite to Cellular Intelligence and entered an agreement with Novo Nordisk to advance STEM-PD, a clinical-stage cell therapy for Parkinson's disease that carries FDA Fast Track Designation. The company works at the intersection of machine learning and regenerative medicine and does not currently publish a public developer API, documentation, SDKs, or other machine-readable API surface.
Somite is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Artificial Intelligence, and Life Sciences.
Somite’s developer surface includes engineering blog and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 3
The organization behind the API